A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

Summary

AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be repeated once every 3, 6 or 9 weeks. Participants may continue study treatment until disease progression, unacceptable toxicity, or consent withdrawal.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Cancer
• Advanced Cancer
• Locally Advanced Carcinoma
• Metastatic Solid Tumor
• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Pancreatic Cancer
• Liver Cancer
• Angiosarcoma
• Solid Tumor

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Angiex, Inc.

Last updated on ClinicalTrials.gov

September 9, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites